Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use
Open accessThe DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index; 6 of the 7 sources its claims cite were checked for support.
Abstract
Methamphetamine (MA) dependence leads to severe physical and psychological issues. Current treatments, including psychosocial therapies and residential rehabilitation, face limitations such as high relapse rates, cost, and accessibility issues. As a result, there is an urgent need for novel approaches to treat MA dependence that are effective, affordable, and accessible to patients. Psilocybin, the active component in numerous mushrooms of the Psilocybe genus, has shown potential for enhancing psychotherapy for various addiction and mental health issues due to its effects on perception, cognition, and affect. Psilocybin-assisted psychotherapy (PAT) has demonstrated initial safety and efficacy in treating alcohol, cocaine, and nicotine dependence. The case presented here describes a 36-year-old transwoman and daily MA user, who participated in a single-arm open-label clinical trial assessing feasibility and safety of PAT for MA dependence at St. Vincent’s Hospital, Sydney. Following inpatient withdrawal management and one session of psilocybin-assisted therapy, she experienced significant cognitive and emotional shifts and sustained MA abstinence. She reported improved mental health over 3 months following treatment completion. She also noted increased self-esteem, mindfulness, and distress tolerance. This study suggests that PAT (following inpatient MA withdrawal management) may offer a scalable, safe, and effective approach for treating MA dependence. However, further research is required to confirm the generalisability and efficacy of PAT for broader populations of people using MA. It is encouraging that this participant, a daily MA user, showed improvements in mood and cognition, in addition to abstinence from MA. Copyright © 2024 Brett, Knock, Watson, Albert, Siefried and Guss.
Overview
CoChat Summary
TL;DR
This paper is a single case report from an open-label safety/feasibility study of psilocybin-assisted psychotherapy (PAT) for methamphetamine dependence. A 36-year-old transwoman who used methamphetamine daily reportedly achieved abstinence after inpatient withdrawal management plus one 25 mg oral psilocybin session, with improved mood, cognition, and self-reported coping over 3 months.
Key findings
- The participant used methamphetamine on 27 of the prior 28 days at screening and had progressed to daily use, smoking 0.1 g to 0.5 g per session over the prior year.
- After treatment, she reported complete abstinence from methamphetamine through 3 months, verified by drug urinalysis.
- Craving scores on a 0–100 visual analogue scale fell from 100 at baseline to 28 at day 28 and 41 at day 90.
- Her DASS-21 score improved from 13/21 at baseline to 6/21 at day 28 and 7/21 at day 90; quality of life on the WEMBS was 54/70 at baseline, 57/70 at day 28, and 50/70 at day 90.
Methods
- Single case from a single-arm, open-label safety and feasibility study conducted in an outpatient setting at St. Vincent’s Hospital, Sydney, with follow-up to 3 months.
- Intervention: 3 preparatory psychotherapy sessions over 2 weeks, inpatient withdrawal management for 5 days, then 25 mg oral psilocybin, followed by 2 integration psychotherapy sessions and return to usual care.
- Outcomes assessed included safety/tolerability, methamphetamine use, craving, depression/anxiety/stress (DASS-21), quality of life (WEMBS), and two qualitative interviews.
Limitations
- The paper explicitly states this is a single case report from a larger study, so its findings cannot establish efficacy or generalizability; it says “more research is required” and that larger randomized controlled studies are needed.
- The text makes evident that the case had no control group and included multiple components (withdrawal management, psychotherapy, psilocybin), so the specific contribution of psilocybin cannot be isolated.
- The participant later admitted to “microdosing” with small amounts of mushrooms on fewer than five occasions about 3 months later, which the text makes evident could complicate interpretation of longer-term outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 1 Not checked · 21 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“other clinically available treatments, including long-stay residential rehabilitation, carry substantial constraints related to access, cost, and scalability (7)”
§ Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use > Introduction The global prevalence of amphetamine (including methamphetamine) use is estimated to be 0.7%, with 11% of those actively using at any given point in time meeting criteria for dependence (1). There are concerns that stimulant dependence is increasing globally because of changes in the global markets of other drugs, including heroin (2). Methamphetamine (MA) dependence is associated with a range of short- and long-term adverse effects, including depressive symptoms, anxiety, psychosis, cardiovascular diseases, and increased risk of HIV and hepatitis C infection (1). Compared to those not dependent, people with methamphetamine dependence have almost seven times greater mortality (1). MA use disproportionately impacts intersectional priority populations including Indigenous People, adolescents, and LGBTQ+ populations (3–5). There are no robustly effective pharmacotherapies available (6), and other clinically available treatments, including long-stay residential rehabilitation, carry substantial constraints related to access, cost, and scalability (7). Specific psychosocial therapies such as cognitive behavioural therapy have demonstrated weak effects, high relapse rates (8), and poor consumer acceptability (9). Contingency-management-type treatments have proven costly but are effective in improving treatment retention, abstinence, and frequency of methamphetamine use. However, clinical use of CM has been limited (10), and so there is a dire need to find novel and effective approaches to treat MA dependence. Psilocybin is a serotonin 5-HT2A receptor agonist with very low abuse potential (11). It produces acute and transitory changes to perception, cognition, and affect. Critically, psilocybin, when delivered as an adjunct to addiction-focused psychotherapy, has demonstrated the capacity to safely enhance affective and cognitive impacts of such treatments (12). Psilocybin-assisted psychotherapy (PAT) has been studied as a treatment for a range of mental health and addiction concerns (12). Specifically, psilocybin-assisted psychotherapy has demonstrated safety and efficacy in phase II trials of alcohol dependence (13). There is emerging evidence from early phase trials of nicotine dependence (14) and a recently completed phase II trial of cocaine dependence. There is strong rationale for investigating psilocybin-assisted psychotherapy as a novel treatment for MA dependence (15).
What the sources say
- Partly supportedcites [7] McKetin, 2012, Evaluating the impact of community-based treatment options on methamphetamine use: findings from the M ethamphetamine T reatment E valuation S tudy (MATES), Addiction sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes residential rehabilitation as having expensive running costs and questions whether its time-limited benefits outweigh them. The Participants and procedure section describes longer residential stays, but the paper does not establish constraints on access or scalability. It also does not extend those constraints to other clinically available treatments. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“she scored >60% on each of the seven subscales of the mystical experience questionnaire, indicating a “complete mystical experience” (20)”
§ Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use > Case presentation > Study treatment
What the sources say
- Supportedcites [20] Barrett, 2015, Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin, J Psychopharmacol source
The Methods > Analysis passage defines a complete mystical experience on the seven-subscale MEQ43 using scores of at least 60% on six qualifying subscales. Scoring above 60% on all seven therefore meets that criterion. The cited paper supplies the classification rule, not the reported score for PM. (LLM, conf=0.90)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There is emerging evidence from early phase trials of nicotine dependence (14)”
§ Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use > Introduction The global prevalence of amphetamine (including methamphetamine) use is estimated to be 0.7%, with 11% of those actively using at any given point in time meeting criteria for dependence (1). There are concerns that stimulant dependence is increasing globally because of changes in the global markets of other drugs, including heroin (2). Methamphetamine (MA) dependence is associated with a range of short- and long-term adverse effects, including depressive symptoms, anxiety, psychosis, cardiovascular diseases, and increased risk of HIV and hepatitis C infection (1). Compared to those not dependent, people with methamphetamine dependence have almost seven times greater mortality (1). MA use disproportionately impacts intersectional priority populations including Indigenous People, adolescents, and LGBTQ+ populations (3–5). There are no robustly effective pharmacotherapies available (6), and other clinically available treatments, including long-stay residential rehabilitation, carry substantial constraints related to access, cost, and scalability (7). Specific psychosocial therapies such as cognitive behavioural therapy have demonstrated weak effects, high relapse rates (8), and poor consumer acceptability (9). Contingency-management-type treatments have proven costly but are effective in improving treatment retention, abstinence, and frequency of methamphetamine use. However, clinical use of CM has been limited (10), and so there is a dire need to find novel and effective approaches to treat MA dependence. Psilocybin is a serotonin 5-HT2A receptor agonist with very low abuse potential (11). It produces acute and transitory changes to perception, cognition, and affect. Critically, psilocybin, when delivered as an adjunct to addiction-focused psychotherapy, has demonstrated the capacity to safely enhance affective and cognitive impacts of such treatments (12). Psilocybin-assisted psychotherapy (PAT) has been studied as a treatment for a range of mental health and addiction concerns (12). Specifically, psilocybin-assisted psychotherapy has demonstrated safety and efficacy in phase II trials of alcohol dependence (13). There is emerging evidence from early phase trials of nicotine dependence (14) and a recently completed phase II trial of cocaine dependence. There is strong rationale for investigating psilocybin-assisted psychotherapy as a novel treatment for MA dependence (15).
What the sources say
- Supportedcites [14] Johnson, 2017, Long-term follow-up of psilocybin-facilitated smoking cessation, Am J Drug Alcohol Abuse source
The Introduction describes an open-label pilot intervention combining psilocybin with cognitive behavioral therapy for smoking cessation and reports its initial abstinence results. The Discussion reports long-term follow-up findings while cautioning that the small, uncontrolled study cannot establish efficacy. This supports the claim of emerging early-phase evidence, not a definitive treatment effect. (LLM, conf=0.90)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are no robustly effective pharmacotherapies available (6)”
§ Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use > Introduction The global prevalence of amphetamine (including methamphetamine) use is estimated to be 0.7%, with 11% of those actively using at any given point in time meeting criteria for dependence (1). There are concerns that stimulant dependence is increasing globally because of changes in the global markets of other drugs, including heroin (2). Methamphetamine (MA) dependence is associated with a range of short- and long-term adverse effects, including depressive symptoms, anxiety, psychosis, cardiovascular diseases, and increased risk of HIV and hepatitis C infection (1). Compared to those not dependent, people with methamphetamine dependence have almost seven times greater mortality (1). MA use disproportionately impacts intersectional priority populations including Indigenous People, adolescents, and LGBTQ+ populations (3–5). There are no robustly effective pharmacotherapies available (6), and other clinically available treatments, including long-stay residential rehabilitation, carry substantial constraints related to access, cost, and scalability (7). Specific psychosocial therapies such as cognitive behavioural therapy have demonstrated weak effects, high relapse rates (8), and poor consumer acceptability (9). Contingency-management-type treatments have proven costly but are effective in improving treatment retention, abstinence, and frequency of methamphetamine use. However, clinical use of CM has been limited (10), and so there is a dire need to find novel and effective approaches to treat MA dependence. Psilocybin is a serotonin 5-HT2A receptor agonist with very low abuse potential (11). It produces acute and transitory changes to perception, cognition, and affect. Critically, psilocybin, when delivered as an adjunct to addiction-focused psychotherapy, has demonstrated the capacity to safely enhance affective and cognitive impacts of such treatments (12). Psilocybin-assisted psychotherapy (PAT) has been studied as a treatment for a range of mental health and addiction concerns (12). Specifically, psilocybin-assisted psychotherapy has demonstrated safety and efficacy in phase II trials of alcohol dependence (13). There is emerging evidence from early phase trials of nicotine dependence (14) and a recently completed phase II trial of cocaine dependence. There is strong rationale for investigating psilocybin-assisted psychotherapy as a novel treatment for MA dependence (15).
What the sources say
- Supportedcites [6] Siefried, 2020, Pharmacological treatment of methamphetamine/amphetamine dependence: A systematic review, CNS Drugs source
The Conclusions state that no pharmacotherapy for amphetamine/methamphetamine dependence has provided convincing results. The Discussion’s Summary of Evidence likewise says the reviewed studies do not permit recommending any pharmacotherapy as effective, while acknowledging promising signals. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite her initial goal being to reduce MA use, she shifted to complete abstinence following PAT.”
§ Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use > Case presentation > Study treatment
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
9 more claims
Create a free account to see all 29 claims and every source verdict.
- It may state two separate claims as one. 10
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two participants underwent inpatient withdrawal management prior to the psilocybin dosing day, described elsewhere [22].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [22]
Experimental — accuracy not yet measured
Citations
Cites
The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., Parkinson, J., Secker, J., & Stewart-Brown, S. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-63 · Cited by 5,031 · cited 1×
“Participants were followed weekly for 1 month and then fi nally at 3 months following the psilocybin dose to measure safety and tolerability; change in methamphetamine use over the prior 28 days (17); MA cravings; depression, anxiety, and stress ratings (18); and quality of life (19).”
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use
Robinson, S. M., Sobell, L. C., Sobell, M. B., & Leo, G. I. (2014) · Psychology of Addictive Behaviors · doi:10.1037/a0030992 · Cited by 699
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696 · cited 1×
“There is emerging evidence from early phase trials of nicotine dependence (14) and a recently completed phase II trial of cocaine dependence.”
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637 · cited 1×
“During subsequent self-assessment, she scored >60% on each of the seven subscales of the mystical experience questionnaire, indicating a “ complete mystical experience ” (20) and scored a total of 80 out of 100 on the emotional break through inventory (21).”
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413 · cited 1×
“During subsequent self-assessment, she scored >60% on each of the seven subscales of the mystical experience questionnaire, indicating a “ complete mystical experience ” (20) and scored a total of 80 out of 100 on the emotional break through inventory (21).”
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354 · cited 2×
“Psilocybin is a serotonin 5-HT 2A receptor agonist with very low abuse potential (11).”
Responding to global stimulant use: challenges and opportunities
Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., Ali, R., Tran, L. T., Rehm, J., Torrens, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32230-5 · Cited by 310
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194 · cited 3×
“Pharmacotherapy alone and psychosocial therapy alone have shown poor results in terms of lasting treatment effects (6, 8).”
Self-citationMcKetin, R., Najman, J. M., Baker, A. L., Lubman, D. I., Dawe, S., Ali, R., Lee, N. K., Mattick, R. P., & Mamun, A. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03933.x · Cited by 147
The relationship between crystalline methamphetamine use and methamphetamine dependence
McKetin, R., Kelly, E., & McLaren, J. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.007 · Cited by 145 · cited 1×
“MA use disproportionately impacts intersectional priority populations including Indigenous People, adolescents, and LGBTQ+ populations (3 – 5).”
Therapeutic effect of psilocybin in addiction: A systematic review
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1134454 · Cited by 127 · cited 1×
“…as a predictor of psychiatrists not believing that psychedelics hold potential for treatment substance use disorders (22, 23), despite evidence that the abuse potential of psychedelics is negligible (11) and growing evidence of the ef fi cacy and safety of PAT to treat substance use disorders (24).”
Amphetamine Withdrawal: I. Reliability, Validity and Factor Structure of a Measure
Srisurapanont, M., Jarusuraisin, N., & Jittiwutikan, J. (1999) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.1999.00517.x · Cited by 126 · cited 1×
“The latter was assessed by a medical of fi cer prior to psilocybin dosing with the assistance of the Amphetamine Withdrawal Scale (16) and urine drug analysis.”
Global Methamphetamine Trends: An Evolving Problem
Stoneberg, D. M., Shukla, R. K., & Magness, M. B. (2018) · International Criminal Justice Review · doi:10.1177/1057567717730104 · Cited by 81 · cited 1×
“There are concerns that stimulant dependence is increasing globally because of changes in the global markets of other drugs, including heroin (2).”
The therapeutic potential of psilocybin: a systematic review
van Amsterdam, J., & van den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047929 · Cited by 74
Barnett, B. S., Beaussant, Y., King, F., & Doblin, R. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1957183 · Cited by 71 · cited 1×
“…psychedelics was identi fi ed as a predictor of psychiatrists not believing that psychedelics hold potential for treatment substance use disorders (22, 23), despite evidence that the abuse potential of psychedelics is negligible (11) and growing evidence of the ef fi cacy and safety of PAT to…”
Acheson, L. S., Williams, B. H., Farrell, M., McKetin, R., Ezard, N., & Siefried, K. J. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13511 · Cited by 49 · cited 2×
“The impact of inpatient withdrawal on treatment outcomes is unknown (25).”
Self-citationLevels of methamphetamine use and addiction among gay, bisexual, and other men who have sex with men
Solomon, T. M., Halkitis, P. N., Moeller, R. W., & Pappas, M. K. (2011) · Addiction Research & Theory · doi:10.3109/16066359.2011.552816 · Cited by 32
Psychosocial interventions for stimulant use disorder
Minozzi, S., Saulle, R., Amato, L., Traccis, F., & Agabio, R. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011866.pub3 · Cited by 32 · cited 3×
“Psychosocial therapies for MA dependence generally do not require withdrawal management prior to treatment initiation in most community settings (8).”
Addiction specialists' attitudes toward psychedelics: A National Survey
Kim, A., & Suzuki, J. (2023) · American Journal on Addictions · doi:10.1111/ajad.13461 · Cited by 22 · cited 1×
“…was identi fi ed as a predictor of psychiatrists not believing that psychedelics hold potential for treatment substance use disorders (22, 23), despite evidence that the abuse potential of psychedelics is negligible (11) and growing evidence of the ef fi cacy and safety of PAT to treat…”
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123424 · Cited by 16
Self-citationQualitative understandings of access to primary care services for consumers who use methamphetamine
Ward, B., Lane, R., Quinn, B., & Russell, G. M. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-07-20-5550 · Cited by 15 · cited 1×
“Speci fi c psychosocial therapies such as cognitive behavioural therapy have demonstrated weak effects, high relapse rates (8), and poor consumer acceptability (9).”
Implementation of Contingency Management at a Large VA Addiction Treatment Center
Ruan, H., Bullock, C. L., & Reger, G. M. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700242 · Cited by 12 · cited 1×
“However, clinical use of CM has been limited (10), and so there is a dire need to fi nd novel and effective approaches to treat MA dependence.”
Research works printed but not linked: 2
- MacLean, 2017, Critical considerations in responding to crystal methamphetamine use in Australian Aboriginal communities, Drug Alcohol Rev, 36, 10.1111/dar.2017.36.issue-4 · doi:10.1111/dar.2017.36.issue-4
- Osman, 2012, The depression anxiety stress Scales—21 (DASS-21): further examination of dimensions, scale reliability, and correlates, J Clin Psychol, 68, 10.1002/jclp.2012.68.issue-12 · doi:10.1002/jclp.2012.68.issue-12
Cited by
The Emergence of Psilocybin in Psychiatry and Neuroscience
Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040555 · Cited by 16
Zhang, Y., Yang, L., Zhang, Q., Li, C., Mao, F., & Zhuo, C. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03410-7 · Cited by 10
“Future studies, including clinical trials, are essential to con fi rm the mechanisms and therapeutic potential of psilocybin in suicide prevention.”
Knock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9
Self-citationKnock, E., Siefried, K. J., Bedi, G., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116026 · Cited by 1
Self-citationBahceci, D., Siefried, K. J., Steele, M., Harrod, M., Bell, G., Barratt, M. J., Nicholas, C. R. N., Rodgers, A., Hendricks, P. S., Stauffer, C. S., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112699 · Cited by 1
Self-citation
Metadata
- Authors
- Brett, J., Knock, E., Watson, K., Albert, S., Siefried, K. J., & Guss, J.
- Affiliations
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- New York University (US)
- Corresponding author
- Brett, Jonathan
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2024-12-06
- Volume
- 15
- Pages
- 1490907-1490907
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC11659228
- OpenAlex
- W4405122998
- Cited by
- 7
- References
- 25
- Citations by year
- 2026: 2 · 2025: 5
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by)
- Funders
- St. Vincent's Clinic Foundation
- Usona Institute
- Medical Research Council
- National Health and Medical Research Council (1196900, 1196560)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- psilocybin-assisted therapy, methamphetamine dependence, abstinence, transgender women, feasibility and safety, mindfulness, distress tolerance, self-esteem, mood improvement, cognitive change
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.